Virios Therapeutics Llc (VIRI)

NASDAQ
6.04
-0.04(-0.66%)
After Hours
6.04
0.00(0.00%)
- Real-time Data
  • Volume:
    81,099
  • Bid/Ask:
    5.53/6.08
  • Day's Range:
    5.76 - 6.12

VIRI Overview

Prev. Close
6.08
Day's Range
5.76-6.12
Revenue
-
Open
6.02
52 wk Range
4.6-16.71
EPS
-1.47
Volume
81,099
Market Cap
50.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
127,502
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
8,330,390
Next Earnings Date
Sep 01, 2021
What is your sentiment on Virios Therapeutics Llc?
or
Market is currently closed. Voting is open during market hours.

Virios Therapeutics Llc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyBuy

Virios Therapeutics Llc Company Profile

Virios Therapeutics Llc Company Profile

Employees
3

Virios Therapeutics LLC is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. IMC-1 combines two specific mechanisms of action purposely designed to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or down-regulating HSV-1 from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication and thus inhibits upregulation of the HSV-1 virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (COX-2) and to a lesser degree COX-1, enzymes used by HSV-1 to amplify or accelerate its own replication.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.